Burdach Stefan E G, Westhoff Mike-Andrew, Steinhauser Maximilian Felix, Debatin Klaus-Michael
Department of Pediatrics and Children's Cancer Research Center (CCRC), Technische Universität München, Koelner Platz 1, 80804, Munich, Germany.
CCC München-Comprehensive Cancer Center and German Translational Cancer Research Consortium (DKTK), Partner Site Munich, Munich, Germany.
Mol Cell Pediatr. 2018 Aug 31;5(1):6. doi: 10.1186/s40348-018-0084-3.
Outcome in treatment of childhood cancers has improved dramatically since the 1970s. This success was largely achieved by the implementation of cooperative clinical research trial groups that standardized and developed treatment of childhood cancer. Nevertheless, outcome in certain types of malignancies is still unfavorable. Intensification of conventional chemotherapy and radiotherapy improved outcome only marginally at the cost of acute and long-term side effects. Hence, it is necessary to develop targeted therapy strategies.Here, we review the developments and perspectives in precision medicine in pediatric oncology with a special focus on targeted drug therapies like kinase inhibitors and inducers of apoptosis, the impact of cancer genome sequencing and immunotherapy.
自20世纪70年代以来,儿童癌症的治疗结果有了显著改善。这一成功很大程度上得益于合作临床研究试验组的实施,这些试验组规范并发展了儿童癌症的治疗方法。然而,某些类型恶性肿瘤的治疗结果仍然不容乐观。强化传统化疗和放疗仅在一定程度上改善了治疗结果,却要付出急性和长期副作用的代价。因此,有必要制定靶向治疗策略。在此,我们回顾了儿科肿瘤学精准医学的发展和前景,特别关注激酶抑制剂和凋亡诱导剂等靶向药物治疗、癌症基因组测序的影响以及免疫治疗。